In light of the results obtained with clofazimine on B-CLL cells and in the orthotopic melanoma model, and of indications of expression of Kv1.3 in pancreatic cancer tissues, we investigated whether this drug can be used against PDAC in an orthotopic xenograft model. Here, KCNA3 is linked to melanoma.